|
LYB001
Vaccine candidate against COVID-19
Pharmaceutical compound
LYB001 is a COVID-19 vaccine candidate developed by Yantai Patronus Biotech Co., Ltd.[1][2][3][4]
It was found to be safe and well tolerated.[5]
References
- ^ "Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy adults: a randomized, double blinded, placebo-controlled phase I trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
- ^ "A Phase I Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 18 November 2021. NCT05125926. Retrieved 18 November 2021.
- ^ "Immunogenicity and safety of a SARS-CoV-2 Vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
- ^ "Phase II and III Trial of a SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 30 November 2021. NCT05137444. Retrieved 30 November 2021.
- ^ Tang R, Zeng Y, Zhou Y, Liang Q, Kang W, Yang Z, et al. (2 May 2024). "Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study". Expert Review of Vaccines. 23 (1): 498–509. doi:10.1080/14760584.2024.2337051. PMID 38695310.
|
|---|
| Development | |
|---|
| Classes | |
|---|
| Administration | |
|---|
| Vaccines | |
|---|
Inventors/
researchers | |
|---|
| Controversy | |
|---|
| Related | |
|---|
|
|
|---|
| | | | | | Institutions |
|---|
Hospitals and
medical clinics | |
|---|
| Organizations | | Health
institutes | |
|---|
Pandemic
institutes | |
|---|
| Relief funds | |
|---|
|
|---|
|
| | Data (templates) |
|---|
| Global | |
|---|
| Africa | |
|---|
| Americas | |
|---|
| Asia | |
|---|
| Europe | |
|---|
| Oceania | |
|---|
| Others | |
|---|
|
|
|
|
.svg){kind=small}
.png){kind=small}
